Spectral medical provides tigris trial update

Toronto, dec. 14, 2023 (globe newswire) -- spectral medical inc. (“spectral” or the “company”) (tsx: edt), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the company's tigris trial, a phase 3 follow-on study evaluating the use of polymyxin b hemoperfusion (“pmx”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
BAX Ratings Summary
BAX Quant Ranking